MedPath

Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms

Not Applicable
Completed
Conditions
Dementia
Interventions
Procedure: telemedicine
Registration Number
NCT02472015
Lead Sponsor
University Hospital, Toulouse
Brief Summary

Telemedicine may facilitate adequate treatment of Neuropsychiatric symptoms (NPS) by identifying underlying causes and tailoring a treatment plan (pharmacological or non-pharmacologic treatments including provision of staff education and support, training in problem solving, and targeted therapy directed at the underlying causes for specific behaviors).

Detailed Description

During a 6-months period, patients will be included in both arms, whenever they present a disruptive NPS that requires a specialist consultation based on the long-term care facility (LTCF) staff judgment. In the intervention group, a telemedicine (TM) consultation between the LTCF staff (medical and nurse staff) and the Memory Center from the University Hospital, will occur at inclusion (T0). Then, a second TM consultation will occur at 1 month (T1). In the control group management of NPS will be done as usual care. In both groups, patients' parameters such as non-programmed hospitalizations and/or consultations due to disruptive NPS, psychotropic drugs use, and health costs, will be evaluated at inclusion, 1 month and at 2 months. Acceptability of the TM among the LTCF staff will be assessed during the study in the intervention group.

The two university hospitals are composed of a group of institutions for elderly people located near Toulouse and Limoges.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
143
Inclusion Criteria
  • patient aged 65 or more, with a dementia diagnosed by a specialist or the general practitioner;
  • patient presenting with a disruptive NPS as defined in French Haute Autorité de Santé (HAS) recommendations (2009), that requires a specialist consultation based on the LTCF staff judgment;
  • informed and written consent by the patient or the legal representative or the reliable person when appropriate;
  • general practitioner agreement.
Exclusion Criteria
  • patient's life expectancy less than 6 months;
  • Non agreement of study participation of patients or legal representative or the reliable person when appropriate.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
telemedicinetelemedicinepatients who will have telemedicine
Primary Outcome Measures
NameTimeMethod
Acceptability of the TM among the LTCF staff6 months

Acceptability of the telemedicine (TM) among the LTCF staff which will be assessed in the intervention group by quantitative indicators (proportion of the solicitation of the TM solution among patients with disruptive NPS, the delay to obtain a TM consultation and the number of the staff participants at each TM consultation) and qualitative indicators (staff global satisfaction will be evaluated by focus groups and interviewing).

Secondary Outcome Measures
NameTimeMethod
The psychotropic drugs used6 months

Description of psychotropic drugs used in both groups

describe the health costs6 months

Description of the health costs in both groups

describe the estimation of the cluster effect ("design effect")6 months

Estimation of the cluster effect ("design effect") in both groups

Rate of non-programmed hospitalizations and/or consultation due to disruptive NPS6 months

Calculation of the rate of non-programmed hospitalizations and/or consultation due to disruptive NPS in both groups

Trial Locations

Locations (2)

UHLimoges

🇫🇷

Limoges, France

UHToulouse

🇫🇷

Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath